COVID-19-related research market cap changes in biopharma companies Feb 2020

In the wake of the novel coronavirus outbreak, the biopharmaceutical company with the highest market capitalization change of over nine billion dollars - in the given time range - was Gilead Sciences as they started phase three trials of their antiviral drug remdesivir for the treatment of COVID-19. This statistic depicts the market capitalization changes of select biopharmaceutical companies which are involved in R&D on the novel coronavirus to find treatments or vaccines, in regards to the period from January 20 to February 25, 2020.

Market capitalization changes of select biopharmaceutical companies involved in coronavirus (COVID-19) research from January 20 to February 25, 2020

Loading statistic...
You need to log in to download this statistic
Register for free
Already a member?
Log in
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

February 2020

Region

Worldwide

Survey time period

January 20 to February 25, 2020

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Single Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 / Month *
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract; Prices do not include sales tax.

Statistics on "Coronavirus (COVID-19) in Japan"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.